MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:FSE) announced on November 16, 2026, that its AI-driven voice analytics technology has reached up to 83% accuracy in intoxication detection under certain testing conditions, marking a key product development milestone ahead of its first commercial pilot.
Key Investor Takeaways
- MindBio reports up to 83% accuracy in voice-based intoxication detection and says its prediction models, with and without sober baseline tracking, exceed the accuracy of some commonly used commercially available cheek swab tests.
- The November 16, 2026, private placement targets up to CA$350,000 plus debt conversion to fund working capital and listing expenses amid the shift to commercialization.
- Next-generation Edge AI kiosks integrate hardware and software for enterprise use in mining, aviation, construction, and law enforcement.
- Further testing over the next two to three weeks precedes the first commercial pilot launch, initially in Spanish.
- Market capitalization stood at roughly CA$728,000 following the November 13 close at CA$0.10.
- CEO Justin Hanka emphasized the voice as an untapped biological data source for scalable, simple intoxication screening.
- The company continues advancing its AI prediction models refined over six months of optimization work.
83% Accuracy Milestone and Financing
In the release, the company stated that its prediction models, with and without sober baseline tracking, now exceed the accuracy of some commonly used commercially available cheek swab tests. Further human testing is planned over the next two to three weeks before launching the first commercial pilot product, initially in Spanish, integrating its voice AI software with purpose-built Edge AI kiosks.
MindBio also announced a non-brokered private placement of up to 3,888,889 units at CA$0.09 per unit for gross proceeds of up to CA$350,000. Each unit includes one common share and one-half of one warrant exercisable at CA$0.16 for 36 months. Proceeds will support general working capital, annual audit and legal expenses, and OTC and CSE listing costs. The company will also convert CA$38,000 of debt into 422,222 units on the same terms.
MindBio has been focused on refining its proprietary intoxication prediction models over the past six months, emphasizing predictive accuracy, reliability, and robustness. The company completed manufacturing of its next-generation Edge AI Intoxication Detection Kiosk on October 14, 2026. The platform targets enterprise environments including mining, aviation, construction, and law enforcement.
Safety Protocols for Intoxication Need Better Tools
MindBio stated that large-scale screening for drug and alcohol intoxication could help prevent unnecessary harm by identifying signs of physiological decline. The company cited estimates suggesting that suicide risk increases 10–20 times during periods of heavy intoxication. It also reported that alcohol is involved in 40–50% of suicides and that the global economic cost of alcohol-related harm is approximately US$1.6 trillion.
Several factors can contribute to an increased risk of addiction and substance abuse, including limited parental monitoring, peer pressure, socioeconomic circumstances, the type of substance, stress, drug availability, and occupation, according to the American Addiction Centers. The organization identifies the mining industry as "particularly conducive to substance abuse," citing workplace stress, physical demands, and injuries associated with prolonged labor.
The global biotechnology market is also expected to experience substantial growth. According to Grand View Research, "The global biotechnology market size was estimated at US$1.55 trillion in 2023 and is projected to reach US$3.88 trillion by 2030, growing at a CAGR of 13.96% from 2024 to 2030." Meanwhile, in September 2025, MarketsandMarkets described the AI detector market as "undergoing rapid expansion," with its value projected to increase from approximately US$0.58 billion in 2025 to US$2.06 billion by 2030.
What Comes Next for MindBio?
Management highlighted the transition from intensive R&D toward commercial deployment, with immediate focus on improving predictive performance, real-world demonstrations, and establishing pathways into safety-critical industries.
CEO Justin Hanka said, "We are now approaching an exciting inflection point for the Company as we transition from intensive research and development towards commercial deployment. Our immediate focus is on further improving predictive performance, demonstrating the technology in real-world operating environments and establishing a commercial pathway into industries where safety is paramount. Ultimately, our ambition is to make intoxication screening as simple as speaking into a device, transforming the economics of drug and alcohol testing while helping to prevent accidents, reduce injuries and save lives."
Ownership and Share Structure1
Management and insiders own approximately 2.10% of MindBio Therapeutics, with retail investors accounting for the balance.
The largest disclosed holder is Justin Hanka at about 2.09%.
The company has roughly 7.28 million shares outstanding and a market capitalization of about CA$728,300.
No verified insider open-market buys or sells were found for the last six months.
2 series of warrants remain outstanding. Public records show one historical share restructure.
Common Questions from Investors
What accuracy level did MindBio report in its latest testing?
Up to 83% accuracy in intoxication detection under certain conditions, exceeding some commercial cheek swab tests, per the November 16, 2026 press release.
How is MindBio funding its commercialization efforts?
Through a non-brokered private placement of up to CA$350,000 at CA$0.09 per unit plus CA$38,000 debt conversion, both announced November 16, 2026.
What is the next step after the accuracy milestone?
Further extensive human testing is planned over the next two to three weeks before the company launches its first commercial pilot product.
Which industries is the technology targeting?
Mining, aviation, construction, and law enforcement for enterprise intoxication and fatigue detection.
| Want to be the first to know about interesting Life Sciences Tools & Diagnostics investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of MindBio Therapeutics Corp.
- Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
Ownership percentages, named holders, share count, market capitalization, and the 52-week range for MindBio Therapeutics were compiled from company public filings and investor materials, exchange notices, insider-trade reports (SEDI / equivalent), and third-party data providers. Figures are as of 2026-11-16 unless a source was dated earlier. Pie slices are normalized to 100% of basic shares outstanding; retail is the residual after disclosed institutions, management, insiders, and strategic holders. Warrant terms are current outstanding series only. Restructures are historical consolidations, splits, and symbol or name changes. Insider buying and selling covers open-market trades from the prior six months through 2026-11-16 and excludes option exercises. These are public-source estimates and can differ from a later official register.


















































